Effect of a long-acting β2-agonist over three months on airway wall vascular remodeling in asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 164, Issue 1, 2001, Pages 117-121

  Orsida, B E ^a   Ward, C ^a   Li, X ^a   Bish, R ^a   Wilson, J W ^a   Thien, F ^a   Walters, E H ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; COLLAGEN TYPE 4; FLUTICASONE; PLACEBO; SALMETEROL;

ADULT; AGED; AIRWAY; ANGIOGENESIS; ARTICLE; ASTHMA; BRONCHUS BIOPSY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LAMINA PROPRIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULARIZATION;

EID: 0035402361     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.164.1.2006003     Document Type: Article

References (28)

1. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
2. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol
3. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma
4. 2-agonist, assessed on airway biopsies and BAL in asthma
5. Vascularity in asthmatic airways: Relation to inhaled steroid dose
6. Topical salmeterol reduces protein content of nasal lavage fluid in response to allergen and histamine challenge: Double blind cross over placebo controlled studies in adults
7. Regular inhaled beta-agonist treatment in bronchial asthma
8. The use of beta-agonists and the risk of death and near death from asthma
9. Potential masking effects of salmeterol on airway inflammation in asthma
10. Present state of the controversy about regular inhaled β agonists in asthma
11. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
12. Measuring efficacy and safety of different inhaled corticosteroid preparations
13. Structure-activity relationship of topically active steroids: The selection of fluticasone propionate
14. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma
15. Effect of short term treatment with low dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo controlled study
16. Inhaled corticosteroid reduced lamina reticularis of the basement membrane by modulation of insulin like growth factor (IGF)-1 expression in bronchial asthma
17. Increased vascularity of the bronchial mucosa in mild asthma
18. Vascularity in asthmatic airways: Relation to inhaled steroid dose
19. Measurement of airway responsiveness to methacholine: Relative importance of the precision of drug delivery and the method of assessing response
20. Theoretic effects of mucus gland discharge on airway resistance in asthma
21. Bronchial vascular engorgement and airflow obstruction
22. Salmeterol reduces BAL IL-8 levels in asthmatics on low dose inhaled corticosteroid
23. Basic fibroblast growth factor induces expression of the PDGF receptor-alpha on human bronchial smooth muscle cells
24. Interleukin 8 (IL-8) as a macrophage-derived mediator of angiogenesis
25. Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma
26. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis
27. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells